The short answer on what patients typically gain

Clinical data across four independent knee studies give a consistent answer: patients treated with ChondroFiller as an ultrasound-guided injectable collagen scaffold typically gain around 30 points on the IKDC functional score — roughly doubling the accepted threshold for a clinically meaningful improvement (the MCID sits at 16.7 points). The most detailed published dataset, the Jerosch et al. post-market clinical follow-up study, recorded a mean gain of 32.4 points at 36 months, placing patients at 80.1 out of 100 on average — up from a pre-treatment baseline of approximately 48/100, a level at which sustained walking and recreational sport are substantially impaired. Every study captured in the manufacturer's April 2025 Clinical Evaluation Report cleared that same MCID threshold.

Beyond the knee, a 26-patient hip cohort reported good or excellent results in 17 of 21 evaluable patients at three to five years; wrist data from second-look arthroscopy showed significantly superior ICRS cartilage grades compared with untreated controls (grade 1 versus grade 3, P=0.002).

These results come from a carefully selected group — younger, active adults with contained focal cartilage defects in otherwise healthy joints, not patients with established osteoarthritis — and that is the first distinction a clinician should establish at assessment.

IKDC scores: how much function improves and when

The IKDC is a patient-completed questionnaire scoring knee function from 0 to 100 — higher numbers reflecting fewer limitations in daily and sporting life. Scores in the high 40s, which characterise the typical treatment candidate, correspond to measurable difficulty with sustained walking, stair-climbing, and low-impact exercise.

Improvements come quickly by clinical standards. A 2016 randomised controlled trial demonstrated statistically significant IKDC gains as early as three months post-treatment (p<0.05), with improvements sustained through the six- and 12-month assessments. A 2024 Bulgarian prospective series (n=17, mean age 31) refined that timing further: gains were significant between baseline and three months, and again at six months, but the six-to-12-month interval produced no statistically significant additional change. Patient-reported function appears to reach a ceiling around six months and hold there through the available follow-up window.

The concept of an MCID — a minimum clinically important difference — gives that plateau practical meaning: it marks the smallest score shift a patient is likely to notice in everyday life. Gains of around 30 points, consistently documented across the available studies, sit roughly twice that perceptible threshold, moving patients from meaningful daily limitation into a functional range compatible with recreational activity and, for many, a return to sport.

One distinction matters here: the plateau reflects subjective function, not the biological repair process. Structural changes on MRI continue to evolve after patient-reported scores level off — a finding addressed in the section that follows.

Longest published knee follow-up currently available is 36 months; peer-reviewed data beyond that point have not yet appeared in the literature.

Tissue fill on MRI: the structural repair timeline

MRI gives clinicians a separate report card from the patient questionnaire — and the two run on noticeably different schedules. MOCART is the scoring system used to grade that imaging: a 0–100 scale that assesses how completely a defect has been filled and how well the repair tissue has integrated with the surrounding native cartilage.

Scores in the early weeks are modest by design. At four weeks, when the injected collagen scaffold is still gelling and the body's own progenitor cells are only beginning to migrate in, MOCART averages around 65.3 — reflecting biology in progress rather than treatment falling short. By 12 months, scores in European knee studies stabilise in the 81.6–84.3 range, which corresponds to more than 80% defect volume fill with sound border integration. Available three-year data suggest that band holds.

The 2016 randomised controlled trial described 'good immediate filling of all treated defects' visible on MRI from the outset, followed by 'impressive maturation of the reconstructed cartilage' on serial imaging over subsequent months. That maturation reflects the scaffold resorbing — as intended — over six to 24 months, leaving behind the patient's own repair tissue rather than a permanent foreign material.

The clinical implication is specific: patients who feel their symptoms have plateaued around six months are not at the end of their structural recovery. Repair tissue continues to consolidate and mature on MRI well after patient-reported function levels off. These are two distinct processes, measured by two distinct tools, and conflating them can lead to premature reassessment or unnecessary anxiety.

How the scaffold recruits the body's own repair cells

The underlying process is called acellular matrix-induced chondrogenesis — meaning a cell-free scaffold that recruits the patient's own progenitor cells rather than delivering donor cells. ChondroFiller contains no biological material of its own beyond the collagen matrix; the repair work is done entirely by cells that migrate in from the surrounding synovium and subchondral bone, using the scaffold as a structured framework in which to anchor and multiply.

A 2025 ex vivo osteochondral model measured how quickly that migration begins: DNA content within the scaffold increased 2.4-fold within just 14 days of placement, confirming that the body's cellular response starts within days rather than weeks.

Those newly recruited cells require time to mature and consolidate before they can reliably bear joint load. A 2024 biomechanical in-vitro study found that ChondroFiller-filled defects under cyclic loading caused similar damage to opposing cartilage as unfilled defects — because the early-stage scaffold lacks the structural stiffness of mature or native cartilage tissue. Post-procedure weight-bearing restrictions exist for this specific reason: the growing cellular population needs a protected environment to consolidate, not merely as a generic precaution.

As the collagen matrix gradually resorbs over the following months, it leaves behind durable autologous repair tissue — the intended outcome of the process, not a sign of treatment wearing off.

Recovery milestones and weight-bearing restrictions

Knowing the approximate schedule helps patients plan around treatment rather than against it.

After image-guided outpatient placement, early weight-bearing is restricted for a specific mechanical reason: as the previous section explained, the immature scaffold cannot yet buffer cyclic joint loads effectively, and the growing cellular population needs a protected environment in which to consolidate. Complying with loading restrictions is part of achieving the outcome, not a precaution to be negotiated away.

Recovery then follows two practical phases. Light jogging is typically introduced somewhere between two and six months, once early cell populations have begun to consolidate and symptoms are easing. High-impact or contact sport is generally deferred to the six-to-twelve-month window. These are approximate ranges — defect size, joint location, and individual fitness all influence the pace.

Patient-reported functional gains are measurable from around three months and largely settle by six months. Structural repair on MRI continues for longer, maturing well into the second year, as the tissue-fill section outlined. Patients who notice their symptoms level off around that halfway point should understand that tissue-level consolidation is still progressing — the two timelines do not align neatly, and a symptom plateau is not stalled healing.

One avoidable complication is overfilling: placing the scaffold proud of the defect surface rather than flush with it tends to produce fibrous rather than hyaline-like repair tissue in the excess material. Second-look arthroscopy data from wrist patients confirm the distinction — flush applications showed none of this, overfilled ones did. Specialist, image-guided placement matters precisely because technique precision here is directly tied to tissue quality.

Who gets these results: patient selection and evidence limits

The results described across this article reflect a specific patient profile — and being clear about that is part of reading the evidence honestly.

Published studies consistently involve younger, active adults (mean age around 31 in the Bulgarian prospective series) with contained, full-thickness focal defects typically under approximately 2 cm², in joints without advanced background arthritis. The hip cohort data illustrate what happens at the margins: among the 26 patients treated for acetabular lesions, those with pre-existing osteoarthritis graded Tönnis 2–3 fared poorly. By contrast, 17 of 21 evaluable patients in the lower-grade group achieved good or excellent results at three to five years — and the difference appears to be primarily about joint background rather than lesion location. The wrist cohort and the four independent knee studies reviewed in the manufacturer's April 2025 Clinical Evaluation Report reflect comparably well-selected, focal presentations.

Two structural limits in the evidence deserve plain acknowledgement. The longest available peer-reviewed follow-up for the knee is 36 months, not five years; whether gains documented to that point hold across a decade is still an open question. Separately, the 2016 RCT enrolled only 13 patients in the ChondroFiller arm — the cross-study IKDC pattern is the more persuasive signal, not any single trial.

For patients with diffuse osteoarthritis, large or poorly contained lesions, or compromised subchondral bone, the published literature does not extend to them. That is not a relative contraindication requiring fine judgement — it is a boundary of the evidence itself, and a meaningfully different clinical conversation.

1. [1] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Implantation of ChondroFiller Liquid as a Scaffold for Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60-month cohort. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759